Clinical Trials Logo

Clinical Trial Summary

The main objective of the study is to monitor health outcomes associated with antiretroviral drugs in a population of HIV-infected patients.


Clinical Trial Description

Time Perspective: Retrospective and Prospective ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01078233
Study type Observational
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase
Start date May 5, 2008
Completion date March 6, 2014

See also
  Status Clinical Trial Phase
Completed NCT01013415 - CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients Phase 1
Active, not recruiting NCT02923713 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Completed NCT01151319 - Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Phase 1
Completed NCT01138605 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Recruiting NCT02593409 - HIV PrEP Priming of Immune Effectors Phase 4
Completed NCT00557245 - Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples Phase 3
Withdrawn NCT00984152 - Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women Phase 3
Completed NCT00799058 - A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States Phase 1/Phase 2
Completed NCT01159275 - Lopinavir (LPV) Dose Reduction Phase 1/Phase 2
Completed NCT01281813 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01078246 - Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Active, not recruiting NCT03027297 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01139905 - Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children Phase 2
Completed NCT01033760 - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) Phase 3
Completed NCT00830804 - Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults Phase 2
Completed NCT01074931 - Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China N/A